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A B S T R A C T
Myeloid sarcoma is a tumor mass with extramedullary growth pattern, composed of myeloblasts or immature myeloid
cells. The development of myeloid sarcomamay precede or concur with acute or chronic myeloid leukemia (AML or CML)
or other myeloproliferative diseases or myelodysplastic syndromes (MDS). Isolated myeloid sarcoma of the breast is very
rare. A case is presented of a 25-year-old, previously healthy woman that presented to our department for a palpable
node, 5x2 cm in size, in the upper medial quadrant of her left breast. Fine needle aspiration (FNA) produced a sample
consisting of medium sized blasts. Additional work-up revealed anemia, thrombocytopenia and leukocytosis, along with
atypical blasts detected in peripheral blood and bone marrow smear. Based on the morphology, cytochemical characteris-
tics and immature cell immunophenotype, it was considered a case of acute myeloid leukemia without maturation. In
spite of intensive chemotherapy, the patient died within a year of diagnosis. In cases of isolated breast myeloid sarcoma,
the diagnosis can be missed if the possibility of myeloid sarcoma is not remembered on differential diagnosis of a breast
neoplasm.
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Introduction
Myeloid sarcoma is an extramedullary tumor mass
composed of myeloblasts or immature myeloid cells1.
These tumors are known by a variety of synonyms in lite-
rature, including chloroma, granulocytic sarcoma, mono-
cytic sarcoma, myeloblastoma and extramedullary mye-
loid tumor2. Myeloid sarcoma was first described by A.
Burns in 18113, but the term chloroma was first used by
King in 1853 due to the presence of myeloperoxidase
which gives these tumors the green color4. The develop-
ment of myeloid sarcoma may precede or concur with
acute or chronic myeloid leukemia (AML or CML) or
with other types of myeloproliferative diseases or myelo-
dysplastic syndromes (MDS)1,5. A myeloid sarcoma can
be the first manifestation of relapse in remission in a pre-
viously treated patient with AML1. The most common
sites of myeloid sarcoma include bone (skull, paranasal
sinuses, sternum, ribs, vertebrae and pelvis), lymph no-
des, skin and soft tissue1,2,5–10. According to the litera-
ture, breast tissue is an unusual site of myeloid sarco-
ma5.
Case Report
A 25-year-old female patient presented with a pain-
less, left breast mass discovered on self-examination. She
did not give a history of associated local symptoms such
as nipple discharge or retraction. She was otherwise in
good health. She had no other symptoms, had negative
past medical and family history. On clinical examination,
the lump was in the upper medial quadrant of her left
breast, 5x2 cm in size. Ultrasound scan of the breast
showed a hypoechoic area with well defined margin in
the upper medial quadrant of the left breast. Fine needle
aspiration (FNA) was then performed which showed a
large number of medium sized blasts of dispersed, gentle
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chromatin structure and basophil cytoplasm showing
negative cytochemical reaction to PAS, nonspecific este-
rase and myeloperoxidase (MPO); however, immunocyto-
chemistry yielded positive reaction to MPO and negative
reaction to lymphocytic markers CD20, CD3 and CD10
(Figures 1 and 2). FNA was reported as a myeloid sar-
coma. Additional work-up confirmed this diagnosis.
Laboratory findings were anemia (red blood cell count
3.81012/L, hemoglobin 106 g/L), thrombocytopenia (pla-
telet count 53109/L) and leukocytosis (white blood cell
count 11109/L). Bone marrow aspirate yielded a hyper-
cellular sample of bone marrow with 97% of atypical
blasts of the same cytochemical and immunocytoche-
mical characteristics as the breast aspirate sample (Fig-
ure 3). Atypical blasts were also detected in peripheral
blood smear (76%). On flow cytometry, the phenotype of
the breast and bone marrow aspirate samples showed a
very high percentage expression of the immature mye-
loid cell markers CD34, CD33 and HLA DR. Cytogenetic
analysis of the breast and bone marrow aspirate samples
indicated numerous alterations (81,XX,-X,-X,-7,-8,-8,-9,
add(17p)x2,-18,-18[15]/46,xx[3]). Based on the morphology,
cytochemical characteristics and immature cell immu-
nophenotype, it was considered a case of AML without
maturation. Bone marrow biopsy was also performed
and confirmed the diagnosis of acute leukemia. The pa-
tient was treated with chemotherapy for AML. Remission
was shortly achieved, and then the patient experienced
two relapses in the bone marrow and breast 6 and 12
months later. She died within 1 year of the diagnosis.
Discussion and Conclusion
Myeloid sarcoma is an unusual variant of myeloid ma-
lignancy, presenting as an extramedullary tumor consist-
ing of immature granulocytic cells1,2,5–10. The most com-
mon type of myeloid sarcoma is granulocytic sarcoma
composed of myeloblasts, neutrophils and neutrophil pre-
cursors1. According to the World Health Organization
classification, the tumors are classified into three types
based on the degree of maturation: blastic type (com-
posed primarily of myeloblasts), immature type (com-
posed of myeloblasts and promyelocytes) and differenti-
ated type (composed of promyelocytes and more mature
neutrophils)1.
Monoblastic sarcoma is a less common type of myeloid
sarcoma, which is usually composed of monoblasts and
can precede or concur with acute monoblastic leukemia1.
In cases of transformation of chronic myeloproliferative
disorders, myeloid sarcoma can be associated with tri-lin-
eage hematopoiesis or erythroid precursors or mega-
karyocytes1. Myeloid sarcoma usually develops concur-
rently or following the diagnosis of AML1,5. It vary rarely
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Fig. 2. a) Myeloperoxidase positive tumor cells in breast FNA
(immunocytochemistry, LSAB x1000), b) CD10 negative tumor
cells in breast FNA (immunocytochemistry, LSAB x1000).
a)
b)
precedes leukemia, presenting as an isolated extramedu-
llary tumor mass without blood or bone marrow invol-
vement8,9. About 95% of patients with isolated myeloid
sarcoma develop AML within 1–48 months9. The most
common sites of myeloid sarcoma are bone, lymph nodes,
skin and soft tissue1,2,5–10. Breast tissue is an unusual site
of myeloid sarcoma5. Myeloid sarcoma of the breast de-
velops synchronously or following the diagnosis of AML,
and only 6% develop primarily in the breast without bone
marrow involvement8. In our patient, myeloid sarcoma of
the breast was the first manifestation of the disease.
However, additional examinations revealed immature cel-
ls multiplied in the bone marrow and peripheral blood,
leading to the diagnosis of AML. The majority of patients
with myeloid sarcoma of the breast present with unilat-
eral breast mass, rarely with bilateral mass6. Although
patients are usually female, breast myeloid sarcoma has
also been reported in male patients, presenting with
gynecomastia2. The patients usually had no local symp-
toms such as nipple discharge or retraction6. Our patient
was also female, presented with unilateral breast mass
and had no local symptoms.
According to the literature, the age of patients at pre-
sentation ranges from 16 to 726. Due to the rarity of
myeloid sarcoma of the breast, the diagnosis can be
missed, especially in cases of isolated breast tumor mass
without blood and bone marrow involvement, if the pos-
sibility of myeloid sarcoma is not remembered on differ-
ential diagnosis of a breast neoplasm8. Imaging (mam-
mography, ultrasonography and magnetic resonance) pro-
duces varied appearances and makes it difficult to differ-
entiate myeloid sarcoma from other disorders like breast
carcinoma or lymphoma6. The differential diagnosis in-
cludes a different type of hematopoietic (diffuse large
B-cell lymphoma, anaplastic large-cell lymphoma, lym-
phoblastic lymphoma and Burkitt lymphoma) and non-
-hematopoietic malignancies (breast carcinoma, melano-
ma and sarcoma)2,6–9,11. The differential diagnosis should
also include non-neoplastic conditions like inflammation
and extramedullary hematopoiesis5. Myeloid sarcoma with
a large number of mature myeloid cells and histiocytes
could be misdiagnosed with an acute inflammatory pro-
cess5. Small round cell tumors (neuroblastoma, rhabdo-
myosarcoma, Ewing’s/PNET, and medulloblastoma)
should also be considered, particularly in children1. Im-
munophenotyping by immunocytochemistry and flow cy-
tometry for expression of myelomonocytic antigens are
essential to make a correct diagnosis1,7. An immuno-
cytochemical panel which includes MPO, CD20, CD43
and CD68 can diagnose about 96% of myeloid sarcoma
cases7. In our case, immunocytochemistry yielded posi-
tive reaction to myeloperoxidase and negative reaction to
lymphocytic markers CD20, CD3 and CD10, while flow
cytometry showed a very high percentage expression of
the immature myeloid cell markers CD34, CD33 and
HLA DR. An early and accurate diagnosis of breast
myeloid sarcoma can save patients from unnecessary
surgery. Appropriate chemotherapy may lead to complete
remission or prolong patient survival. Differential diag-
nosis of breast tumor masses should include myeloid sar-
coma of the breast to avoid inappropriate treatment of
this tumor and improve patient prognosis6,7,9.
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Fig. 3. a) Tumor cells in bone marrow aspirate (May-Grünwald-
-Giemsa, x1000), b) myeloperoxidase negative tumor cells








S A @ E T A K
Mijeloidni sarkom je ekstramedularna tumorska masa gra|ena od mijeloblasta ili nezrelih mijeloi~nih stanica. Mo`e
predhoditi ili se javiti istovremeno s akutnom ili kroni~nom mijeloi~nom leukemijom ili drugim tipovina mijeloproli-
ferativnih bolesti ili mijelodisplasti~nih sindroma. Izolirani mijeloidni sarkom dojke javlja se vrlo rijetko. Prikazujemo
slu~aj dvadesetpetogodi{nje, do tada zdrave `ene koja se javlja na kliniku radi palpabilnog ~vora, veli~ine 5x2 cm u
podru~ju gornjeg medijalnog kvadranta lijeve dojke. Citolo{kom punkcijom ~vora tankom iglom dobije se uzorak sred-
nje velikih blasta. U laboratorijskim nalazima na|e se anemija, trombocitopenija i leukocitoza, uz prisutne atipi~ne
blaste u razmazu periferne krvi i punktatu ko{tane sr`i. Obzirom na morfologiju, citokemijska obilje`ja i imunofenotip
nezrelih stanica zaklju~eno je da se radi o akutnoj mijelo~noj leukemiji bez sazrijevanja. Unato~ intezivnoj kemoterapiji
pacijentica umire unutar godinu dana od postavljnja dijagnoze. U slu~aju izoliranog mijeloidnog srkoma dojke mo`e se
previdjeti to~na dijagnoza ako se u diferencijalnoj dijagnozi tumora dojke ne razmi{lja o mijeloidnom sarkomu.
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